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Abstract. Chronic lymphocytic leukemia (CLL) is a common 
hematological malignancy in Western countries. However, this 
disease is very rare in Asian countries. It is not clear whether 
the mechanisms of development of CLL in Caucasians and 
Asians are the same. We compared genetic abnormalities in 
Asian and Caucasian CLL using 250k GeneChip arrays. Both 
Asian and Caucasian CLL had four common genetic abnor-
malities: deletion of 13q14.3, trisomy 12, abnormalities of 
ATM (11q) and abnormalities of 17p. Interestingly, trisomy 12 
and deletion of 13q14.3 were mutually exclusive in both 
groups. We also found that deletions of miR 34b/34c (11q), 
caspase 1/4/5 (11q), Rb1 (13q) and DLC1 (8p) are common 
in both ethnic groups. Asian CLL more frequently had gain 
of 3q and 18q. These suggest that classic genomic changes in 
the Asian and Caucasina CLL are same. Further, we found 
amplification of IRF4 and deletion of the SP140/SP100 genes; 
these genes have been reported as CLL-associated genes 
by previous genome-wide-association study. We have found 
classic genomic abnormalities in Asian CLL as well as novel 
genomic alteration in CLL.
Introduction
Development of cancers are affected by a number of factors 
including environment and genetic background (1). Difference 
in incidence of certain cancers between Asian and Caucasian 
populations is well-recognized (2,3). Environmental and/
or genetic factors may contribute to these differences. For 
example, a high incidence of gastric cancers have been 
reported in Asian countries including Japan (3,4). However, 
the incidence of gastric cancers in Japanese immigrants to 
Hawaii is much lower than the frequency in Japanese in their 
homeland (4,5). This high incidence of gastric cancer appears 
to be strongly influenced by environmental factors. In contrast, 
Asian non-smoking women have a high incidence of non-small 
cell lung cancer (NSCLC) associated with an EGFR mutation 
irrespective of the country where they live (6,7), suggesting a 
germline predisposition for NSCLC with this mutation.
Chronic lymphocytic leukemia (CLL) is a common hema-
tological malignancy in Western countries and it is very rare in 
Asian countries, including Japan (8-10). Furthermore, Asians 
including Japanese immigrants to USA continue to have a low 
incidence of CLL (11,12).
This difference in incidence of CLL between Asians and 
Caucasians is not clear. One possible explanation for the differ-
ence may be that CLL in these two distinct ethnic groups show 
two distinctly different molecular signatures. Another possible 
explanation may be that environmental factors, for example 
an infectious disease, could cause the development of CLL 
and affect the incidence of this disease in two geographically 
distinct regions. This seems less likely because Asians in USA 
also have a low incidence of CLL (11,12). A third possibility 
is germline variation in the general population of these two 
ethnic groups leads to the difference in the incidence of the 
development of CLL.
To identify molecular signatures of Caucasian and Asian 
CLL at the DNA level, we analyzed these cells using high 
resolution single nucleotide polymorphism (SNP) genomic 
oligonucleotide microarrays.
Materials and methods
Samples. Diagnosis of CLL was made based on the updated 
National Cancer Institute-Working Group guidelines (13). All 
leukemic cells expressed CD5, CD19 and CD20. Rearrangement 
of the immunoglobulin heavy chain gene was confirmed by 
PCR as described previously (14). Detailed information of the 
Japanese CLL has been reported previously (14). Leukemic 
cells were collected from 77 cases of Asian CLL (75 Japanese 
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and 2 Chinese) and 55 Caucasian CLL after their informed 
consents were obtained. Institutional committees approved 
the experiments undertaken. DNA was extracted using Qiagen 
DNA extraction kit according to the manufactuer's protocol.
SNP-chip analysis. The extracted DNAs were digested with 
Nsp-I restriction enzyme, amplified and hybridization with 
GeneChip250NspI chip from Affymetrix. Hybridized signals 
were captured on GeneChip Scanner 3000 and the data were 
analyzed by CNAG3.3 software (15,16). Significant differences 
were analyzed using χ2 tests. P-values <0.05 were considered 
statistically significant.
Results
Caucasian and Asian CLL shared the major genomic copy 
number changes. We analyzed 55 cases of Caucasian CLL 
and 77 cases of Asian CLL and found a number of genomic 
abnormalities in both groups. The four well characterized 
genomic abnormalities of CLL, including deletion of 13q14, 
trisomy 12, deletion/UPD of 17p and deletion/UPD of 11q 
(ATM) (17,18), were detected in both groups at a compa-
rable frequency except for deletion/UPD of 11q. Asian v/s 
Caucasian CLL had deletion of 13q14.3 (Asian: 39 cases, 
51%; Caucasian: 26 cases, 48%), trisomy 12 (Asian: 15 cases, 
20%; Caucasian: 16 cases, 30%), abnormalities of 11q (Asian: 
21 cases, 27%; Caucasian: 5 cases, 10%) and abnormalities of 
17p (Asian: 11 cases, 15%; Caucasian: 3 cases, 5%) (Table I). 
Only the frequency of 11q was statistically different (P<0.01). 
Interestingly, deletion of 13q14 and trisomy 12 was mutually 
exclusive in Asian CLL cases (no cases with both trisomy 12 
and 13q14 in the 77 Asian CLL) and nearly same in Caucasian 
CLL (2 of the 55).
Other genomic alterations involved four regions: trisomy 3/
duplication of 3q; trisomy 18/duplication of 18q; deletion 
of 18p; and deletion of 8p (Table II). Asians more frequently 
had either trisomy 3/duplication (dup) of 3q or trisomy 18/
dup18q compared to the Caucasian CLL samples (18 Asian 
v.s. 0 Caucasian CLL sample) (Table II).
Novel candidate target genes associated with development of 
CLL. In this study, we found novel tumor suppressor candidate 
genes often deleted in CLL. Deletion of 11q is frequently 
detected in CLL, involving the ATM gene (26/132 cases 
in total); however, of interest, these 26 cases also had dele-
tion of the microRNA (miR) 34b/34c (Fig. 1A and data not 
shown). A second novel finding was a homozygous deletion of 
11q22.3 involving caspase 1/4/5 genes in an Asian CLL sample 
(Fig. 1A); and seven additional cases had hemizygous deletion 
of these caspase genes (Fig. 1A).
The third finding was near the well-known commonly 
deleted region at 13q14.3 (65 cases in total) involving miR 15-a 
and 16-1 (Table I and Fig. 1B). One case had two distinct 
deletions in this region; one involved miR 15-a and 16-1; 
and the other encompassed the Rb1 gene (Asian CLL #23 in 
Fig. 1B). On close inspection, 36% of cases with deletion of 
13q (23/65 cases), had a deletion of Rb1, suggesting that Rb1 
might be another target of deletion of 13q in CLL.
Fourth, we found that deletion of 8p was common in CLL 
(5 cases) (Table II and Fig. 1C). One Asian-CLL had a very 
small deletion only spanning the DLC1 gene (Asian-CLL #17, 
Fig. 1C). The DLC1 gene may be one of the target genes in 
those samples with deletion of 8p in CLL.
CLL-associated genes are genomically abnormal in CLL 
samples. One Asian-CLL sample had high copy number 
amplification of IRF4 (Fig. 2A). Also, we found that SP140/
SP100 genes were deleted in two Asian and one Caucasian 
CLL samples (Fig. 2B).
A previous genome-wide association study (GWAS) 
identifies SNP sites related to Caucasian CLL (19), including 
SNP-rs872071 (6p25.3) located close to IRF4 gene and 
SNP-rs13397985 (2q37.1) located close to the SP140/SP100 
genes.
Discussion
CLL is extremely rare in Asians (10-12). We have for the first 
time, analyzed a large number of Asian CLL samples, using 
high resolution SNP-chips. Well-known common genomic 
abnormalities (17,18) occured in Asian CLL at a comparable 
frequency as Caucasian CLL except for deletion/UPD of 11q. 
Thus, the classic genomic abnormalities of CLL in these two 
ethnic groups are similar at the DNA level. However, the Asian 
Table I. Four common genomic abnormalities in Asian and 
Caucasian CLL.
 Asian Caucasian P-value
 CLL (77) CLL (55)
13q14 deletion  39 (51%)  26 (48%)    0.60
(sole 13q14 deletion)  12 (16%)   8 (15%)    0.66
11q deletion/UPD  21 (27%)    5 (10%)  <0.01a
17p deletion/UPD  11 (15%)    3   (5%)    0.06
Trisomy 12  15 (20%)  16 (30%)    0.09
Seventy-seven Asian and 55 Caucasian samples of CLL were 
examined with SNP-chip. Four common genomic abnormalities 
are tabulated. The number of cases with indicated abnormalities are 
shown. Sole 13q14 deletion indicates the numbers of cases with only 
13q14 deletion genomic abnormality noted on SNP-chip analysis. 
P-values are also shown. aStatistical siginificance.
Table II. Other common genomic abnormalities found in Asian 
and Caucasian CLL.
 Asian Caucasian P-value
 CLL (77) CLL (55)
Trisomy 3/Dup 3q  6   (8%)  0 (0%)  <0.01a
Trisomy 18/Dup 18q 8 (11%) 0 (0%)  <0.01a
Del 8p  4   (7%) 1 (2%)   0.11
Del 18p  3   (4%) 3 (5%)   0.47 
The number of cases with indicated abnormalities are shown. P-values 
are also shown. aStatistical significance.
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CLL had trisomy 3/duplication of 3q and trisomy 18/duplica-
tion of 18q more frequently than Caucasian CLL samples, 
suggesting that the mechanism of development of CLL in 
Asians is slightly different from Caucasian CLL.
The 18q region contains the BCL2 gene. BCL2 is asso-
ciated with an anti-apoptotic effect and the gene is often 
overexpressed in CLL (20,21). CLL-related loss of 13q14, 
deletes miR15-a/miR 16-1 (22-24). These two microRNAs 
target BCL2 and their deletion causes high expression of 
BCL2 (24,25). Trisomy 18/duplication of 18q may be an alter-
native mechanism to overexpress BCL2. Also, the 3q region 
contains BCL6 (26,27), whose protein antagonizes the TP53 
tumor suppressor gene (27,28).
Seven cases had an 8p deletion (3/77 Asian CLL, 1/55 
Caucasian CLL); and the minimally commonly deleted 
region involved DLC1. In fact, one sample (Asian-CLL 17) 
Figure 1. Novel common target candidate genes in CLL. (A) Representative CLL cases with deletion of 11q. SNP-chip analysis (blue lines) is shown with a 
scheme of the chromosome (top), individual CLL samples and their altered genes (bottom). The arrow on the chromosome panel indicates the position of the 
ATM gene. At the bottom, the three large arrows show the direction of transcription of the target genes; and the diagonal arrow designates the position of the 
microRNAs, miR 34b/34c. The CLL case numbers are shown on the right side (A, Asian; C, Caucasian). (B) Representative CLL cases with deletion of 13q. 
The results of SNP-chip analysis (blue lines) are shown together with the scheme of the chromosome (top). Arrows at the bottom indicate the positions of RB1 
gene and the microRNAs, miR 15-a/16-1. The case numbers are shown on the right side (A, Asian; C, Caucasian). (C) Representative CLL cases with deletion 
of 8p. The result of SNP-chip analysis (blue lines) is shown with the scheme of the chromosome (top) and genes (bottom). The arrow indicates the direction of 
transcription of the DLC1 gene. The case numbers are shown on the right side (A, Asian; C, Caucasian).
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had a deletion that only involved the DLC1 gene. This gene 
encodes the GAP protein and plays an important role in the 
RAS/MAP pathway in a manner similar to NF1 (29,30). This 
gene is frequently deleted in a variety of cancers (30-33). Our 
data suggest that dysregulation of RAS/MAP signal pathway 
occurs in CLL. Reagents targeting this signaling pathway 
could be a promising treatment option for these CLL cases.
Deletion of 8p, duplication of 3q and duplication of 18q are 
also frequently detected in other types of B-cell malignancies 
including lymphomas (34,35). Although a variety of B-cell 
lymphoid malignancies have their distinct clinical features 
(36), they may have dysregulation of common signaling 
pathways. Identification of molecular signatures by SNP-chip 
may lead to re-classification of B-cell malignancies and guide 
clinicians to select optimal therapeutic options targeting the 
dysregulated signaling pathways.
In this study, we also found novel candidate target genes 
in altered chromosomal regions, which may be involved in 
development of CLL. We found that Rb1 on the 13q chromo-
some is frequently deleted when 13q14 is deleted (Fig. 1B). 
This was especially evident in the sample, A-CLL #23, 
which had two distinct deletions in 13q; one targeting 13q14 
(miR15-a/miR16-1) and the other targeting RB1. Thus, Rb1 
may be another tumor suppressor gene on 13q that is altered in 
CLL. In addition, a homozygous deletion of three gene family 
(Casp1/4/5) occurred at 11q in A-CLL #71. Both ATM and 
miR34b/34c genes are on 11q and are frequently deleted in 
CLL. A short distance away are these three caspase genes 
which can also be target genes of this common deleted regions. 
Casp1/4/5 are components of the inflamasome associated with 
inflamation and cell growth (37,38). Deletion of these genes 
may cause an abnormal response of leukemic cells to the 
immuno-surveillance system, allowing proliferation of the 
leukemic cells.
GWAS co-relates presence or absence of a disease 
with the patterns of SNPs in large populations, leading to 
identification of high-risk alleles strongly associated with 
development of the disease (39,40). Interestingly, the genes 
close to these CLL-associated SNP-sites (IRF4 and SP140/
SP100) are moderately often mutated (deleted/amplified) in 
CLL.
In conclusion, we found that: i) the fundamental molecular 
signatures of CLL in the Caucasian and Asian populations are 
fairly similar; ii) novel candidate target genes in commonly 
altered genomic regions include Rb1, Casp1/4/5, DLC1, IRF4 
and SP140/SP100; iii) CLL-associated genes identified by 
the previous GWAS were moderately often mutated in CLL. 
These findings will help to re-classify CLL based on their 
molecular signatures and lead to individualized treatment for 
CLL with reagents targeting signaling pathways which are 
altered in each patient.
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